Matutes E
Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK.
J Clin Pathol. 2002 Mar;55(3):180-3. doi: 10.1136/jcp.55.3.180.
Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative disorders. In addition to the diagnostic value, the expression of certain markers such as p53 or CD38 provides relevant prognostic information to the clinician. Beyond their diagnostic and prognostic value, immunological markers play a major role in the detection of minimal residual disease, enabling the clinician to estimate more accurately the response to chemotherapy. Those monoclonal antibodies that are relevant to the characterisation of the chronic lymphoproliferative disorders and that could be incorporated in a routine practice are discussed.
流式细胞术技术的进步以及可用于检测淋巴细胞上关键功能分子的单克隆抗体，极大地促进了慢性淋巴细胞增殖性疾病的更精确诊断。除了诊断价值外，某些标志物如p53或CD38的表达还为临床医生提供了相关的预后信息。除了诊断和预后价值外，免疫标志物在检测微小残留病方面发挥着重要作用，使临床医生能够更准确地评估化疗反应。本文讨论了那些与慢性淋巴细胞增殖性疾病特征相关且可纳入常规实践的单克隆抗体。
